FORM PTO-1449					Docket No. Application Number						
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)					HU et al. ing Date eccember 23, 1998		Group Art Unit				
U.S. PATENT DOCUMENTS											
Examiner		Document Number	Date		Name	Q _{ress}	SubCb	Filing Date			
					·						
FOREIGN PATENT DOCUMENTS											
		Document Number	Date		Country	Ωesa	SubCla	Translation Yes/No			
BL	DZ	710696	9/30/9	9	Australia						
M	Œ	99/46364	9/99		PCT						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
BL	F	F Anderson, W.F. (1992) Science 256:808-813									
,	EG	Friedman, T. (1992) Nat. Genetics 2:93-98									
	田	H Williams, R.S. (1993) Am. J. Med. Sci. 306:129-136									
	ΕI	Hockel et al. (1993) Arch. Surg. 128:423-429									
	EJ	EJ Guzman et al. (1993) Circ. Res. 73:1202-1207									
·											
		<u> </u>									
						- · · · · · · · · · · · · · · · · · · ·	. <u>.</u>				
								·			
Examiner	Examiner Date Considered 12-18-03										
Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.											

.

.

.

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO						Complete If Known						
INFORMATION DISCLOSURE STATEMENT					TATEMENT							
IN AN APPLICATION												
(use as many sheets as necessar						sary)						
(,,,						*	Application Number. 09/			9/219,442		
							Filing Date December 23, 1998			mber 23, 1998		
					Ì	First Named Inventor Hu, et al.						
							Group Art Unit 1647					
							Examiner Narr	niner Name Saoud, C. Landsman			ζ	
Sheet			1	of		2	Attorney Dock	y Docket Number PF112P2D1				
				•								
	<u></u>	U.S. Patent Document					Date of Publication Pages, Columns, Lines, Where					
Examiner Initials	Cite No.	1	Number	Kind (if kn		Name of Patentee or Cited Docu	Applicant of of Cited Document Relevant Passages or Relement MM-DD-YY Figures Appear			ant		
BL	EA	5,86	1,301		B1	Terman et al.		01-19-1999				
BL	EB		0,693		В1	Eriksson et al.		11-24-1999		<u> </u>		
		-,-,										
-	,		Counting December 17	Daues -		FOREIC	N PATENT D			I Page Cal and the		
Examiner	Cite			oreign Patent Document Kind Co		Name of Patentee or	Applicant of	Date of Publication of Cited Document		Pages, Columns, Lines, Where Relevant		
Initials No.		Office	Number4	Number4 (if known)		Cited Docu	ment	MM-DD-YY		Passages or Relevant Figures Appear	Τę	
15/	EC	EC WO99/46364 Al Human Genome S		Human Genome S	ciences Inc	09-16-1999		rigures Appear	1			
7	20				Λ.	Tunian denome 3	elences, me.	09-10-1999				
m	ED	ĄU	AU-B-7012	8/96	ΑΊ	Genentech, Inc.		09-30-1999				
			0	THER	PRI(OR ART - NON PATE	NT LITERAT	URE DOCUME	NTS		,	
Initials No. (book, magazine, journal, serial, symposium, c						al, serial, symposium, c	ETTERS), title of the article (when appropriate), title of the item catalog, etc.), date, page(s), volume-issue number(s), publisher, city or country where published.					
BL	EE ANDERSON W.E. 601.											
		EF	FRIEDM	FRIEDMAN, T., "A brief history of gene therapy," Nat. Genetics, 2:93-98 (1992).								
		EG	WILLIAMS, R.S. "Southwestern internal medicine conference: prospects for gene therapy of									
- 1	- 1	ischemic heart disease," Am. J. Med. Sci., 306(2): 129-136 (1993).							is for gene ulerapy of	l		
	寸	EH HOCKEL et al., "Therapeutic angiogenesis," Arch. Surg., 128:423-429 (1993).								\dashv		
			<u> </u>									
	ſ	EI	GUZMAI	GUZMAN et al. "Efficient gene transfer into myocardium by direct injection of adenovirus								
			vectors,"	vectors," Circ. Res., 73:1202-1207 (1993).								
1		EJ	BELLOMO et al., "Mice Lacking the Vascular Endothelial Growth Factor-B Gene (Vegfb) Have Smaller Hearts, Dysfunctional Coronary Vasculature, and Impaired Recovery From Cardiac									
- 1			Smaller H	learts,	Dys	functional Coronar	y Vasculatur	e, and Impaire	d Reco	overy From Cardiac		
			Uschemia,	Ischemia," Circ. Research, 89(2): e29-e35 (2000).								
		EK.	(1995).	COCKERILL et al., "Angiogenesis: Models and Modulators" Intl. Rev. Cytology, 159:113-160 (1995).								
		EL	GAMBLE Cell. Bio.	GAMBLE et al., "Regulation of In Vitro Capillary Tube Formation by Anti-Integrin Antibodies," J. Cell. Bio., 121(4): 931-943 (1993).								
	\neg	EM		GOLDSPIEL et al., "Human Gene Therapy," Clinical Pharmacy, 12: 488-505 (1993).								
7	1	EN GRIMMOND et al., "Cloning and Characterization of a Novel Human Gene Related to Vascular								<u></u>		
<u> </u>		Endothelial Growth Factor," Genome Research, 6:124-131 (1996).								-		
Examiner						Date Considered 12-18-03						
	k	_	2 1 2 2				1		10		!	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 bours to complete.' Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office. Washington, DC 20231.

¹ Unique citation designation number. ¹ See attached Kinds of U.S. Patent Documents. ¹ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION						Complete If Known						
(use as many sheets as necessary)						sary)						
							Application N	lumber	09/219,442			
							Filing Date December 23			mber 23, 1998		
							First Named Inventor Hu, et al.			et al.		
. [Group Art Unit 1647					
							Examiner Name Saoud, C.					
Sheet	<u>L</u>		2	of ·	<u> </u>	2	Attorney Docket Number PF112P2D1					
						U.S.	PATENT DOCUMENTS					
Examiner Initials				Name of Patentee o Cited Docu	me of Patentee or Applicant of Of Cited Document Of MM-DD-Y		ment Relevant Passages or Relevant					
·										•		
L						-		1				
						PODE:	TAL DA MONTHON -	0011145				
		- J	Foreign Patent D	Document		FOREIC	GN PATENT D	Date of Publica	ation I	Pages Calverna Lines		
Examiner Initials	Cite No.		Kind Code'		Name of Patentee of Cited Docu	Applicant of ment	of Cited Docur MM-DD-Y	ment	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
							<u> </u>					
								_				
			O	THER	PRIC	R ART - NON PATE	NT LITERAT	URE DOCUME	NTS			
Examin		Cite	Include	name o	f the	author (in CAPITAL L	ETTERS) title (of the article (whe	n annro	priate), title of the item		
Initials	•	No.	(book, ma	igazine,	jouma	ai, senai, symposium, c	atalog, etc.), da	te, page(s), volum	e-issue	number(s), publisher, city		
BL	_	EO	HYDE et	al., "C	Corre	ction of the ion tra 2: 250-255 (1993)	nsport defec	t in cystic fibro	osis tra	insgenic mice by gene		
	-	EP	KAY et a	/ "In	Vivo	Gene Therapy of	Hemophilia	D. Sustained D	Domini.	Co		
BL	HYDE et al., "Correction of the ion transport defect in cystic fibrosis transgenic mice by therapy," Nature, 362: 250-255 (1993). EP KAY et al., "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Face Deficient Dogs," Science, 262:117-119 (1993). EQ KOLODKA et al., "Hepatic Gene Therapy: Efficient Retroviral-Mediated Gene Transfer Hepatocytes in Vivo." Sometic Cell and Molecular Counting, 10(5), 401, 407 (1902).											
Bl	BC KOLODKA et al., "Hepatic Gene Ther						rapy: Efficient Retroviral-Mediated Gene Transfer into Rat					
- ''			Hepatocy	tes in	<u>Vivo,</u>	," Somatic Cell an	d Molecular	Genetics, 19(5	5): 491	-497 (1993).		
	寸	ER	LITWIN	er al.,	"Roh	e of Cytokines in I	indothelial C	ell Functions,	Hum	an Cytokines, 101-129.		
01	/	ES	SHIBUY	A et al	'., 'N	ucleotide sequence	e and express	ion of a novel	humai	n recentor-time timosine		
ES SHIBUYA et al., "Nucleotide sequence and expression of a novel human receptor-ty kinase gene (flt) closely related to the fms family," Oncogene, 519-524 (1990).							1990).					
BL		ET	SILINS et al., "Analysis of the Promoter Region of the Human VEGF-Related Factor Gene"									
	-+	EU	STEWAR	Biochem. Biophys. Res. Comm., 230: 413-418 (1997). STEWART et al. "Insulin delivery by sometic cell cone thereas." Leaf Mal. E. delivery by sometic cell cone thereas."								
BL	335-341 (1993).								1			
BL	.	EV	TOWNSON et al., "Characterization of the Murine VEGF-Related Factor Gene."									
	+	EW	WALSH	Biochem. & Biophys. Res. Comms., 220: 922-928 (1996). WALSH et al., "Gene Therapy for Human Hemoglobinopathies," P.S.E.B.M., 204: 289-300.								
	+											
		$-\!$	1)									
Examiner			/ . ^	. /	0	, —— ——	Date Consid		_			
	<u>/</u>		old	/_	<u>~</u>			12.1	8.0	23		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

¹ Unique citation designation number. ¹ See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.